Key facts today
The U.S. sales launch of Regeneron's atopic dermatitis and prurigo nodularis medication Nemluvio exceeded expectations, showing a promising trajectory in comparison to Dupixent.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
852.27 MXN
92.00 B MXN
296.10 B MXN
104.85 M
About Regeneron Pharmaceuticals, Inc.
Sector
Industry
CEO
Leonard S. Schleifer
Website
Headquarters
Tarrytown
Founded
1988
FIGI
BBG00BNKGPS2
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
REGN: Second Attempt at Strong Support with 1/18 Risk/RewardNASDAQ:REGN is displaying a strong historical bullish trend and is currently offering a potential buying opportunity. After a recent pullback , the stock has reached a key support level , providing a favorable entry point. The risk/reward ratio is highly attractive, with a 1/18 potential to th
REGN Stock - A Strong Buy OpportunityNASDAQ:REGN is in a historical bullish trend , and right now offers a potential buying opportunity:
Discount at Strong Support : After a pullback, the stock has reached a key support level , providing a good entry point.
Excellent Risk/Reward : With a 1:14 ratio to the all-time high (ATH) ,
NASDAQ-REGN at a Crossroads: Breakdown or Breakout?The Market’s Dilemma: Is REGN Ready for a Reversal?
The biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) is hovering at a critical juncture. Trading at $672.98, the stock has plummeted 44.4% from its all-time high of $1211.19 just five months ago. With the RSI at 38.8, the market is edging t
$REGN LongThis is just my observation, but not an advice.
Technical:
REGN touched its two strong trendline since 2020 and 2021.
REGN reached the 50% correction since 2020.
REGN is oversold daily and weekly.
A significant divergence is observable on daily chart.
Price touched SMA 200.
Fundamental:
P/E: 16
REGN is oversold (the most since 1998)🐂 Trade Idea: Long - REGN
🔥 Account Risk: 20.00%
📈 Recommended Product: Stock
🔍 Entry: +/- 738.00
🐿 DCA: No
😫 Stop-Loss: 660.00
🎯 Take-Profit #1: 1,200.00 (50%)
🎯 Trail Rest: Yes
🚨🚨🚨 Important: Don’t forget to always wait for strong confirmation once possible entry zone is reached. Trade ide
REGN possible accumulation at a key levelCM Williams Vix Fix postulates the bottom is forming. REGN did have a pull back to key level and could be accumulating. SRSI levels are in good range. RSI levels are forming to acceptable ranges. Let's see if we get a structure on the key level and positive break out.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
7.88%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
5.42%
Maturity date
Sep 15, 2030
See all REGN bonds
Curated watchlists where REGN is featured.
Related stocks
Frequently Asked Questions
The current price of REGN is 11,544.79 MXN — it hasn't changed in the past 24 hours. Watch REGENERON PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange REGENERON PHARMACEUTICALS INC stocks are traded under the ticker REGN.
REGN stock hasn't changed in a week, the month change is a −12.71% fall, over the last year REGENERON PHARMACEUTICALS INC has showed a −24.63% decrease.
We've gathered analysts' opinions on REGENERON PHARMACEUTICALS INC future price: according to them, REGN price has a max estimate of 21,225.21 MXN and a min estimate of 10,740.23 MXN. Watch REGN chart and read a more detailed REGENERON PHARMACEUTICALS INC stock forecast: see what analysts think of REGENERON PHARMACEUTICALS INC and suggest that you do with its stocks.
REGN reached its all-time high on Aug 29, 2024 with the price of 23,707.11 MXN, and its all-time low was 5,400.50 MXN and was reached on Sep 10, 2019. View more price dynamics on REGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
REGN stock is 0.00% volatile and has beta coefficient of 0.61. Track REGENERON PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is REGENERON PHARMACEUTICALS INC there?
Today REGENERON PHARMACEUTICALS INC has the market capitalization of 1.26 T, it has decreased by −1.11% over the last week.
Yes, you can track REGENERON PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
REGENERON PHARMACEUTICALS INC is going to release the next earnings report on Apr 29, 2025. Keep track of upcoming events with our Earnings Calendar.
REGN earnings for the last quarter are 251.65 MXN per share, whereas the estimation was 235.23 MXN resulting in a 6.98% surprise. The estimated earnings for the next quarter are 177.48 MXN per share. See more details about REGENERON PHARMACEUTICALS INC earnings.
REGENERON PHARMACEUTICALS INC revenue for the last quarter amounts to 79.00 B MXN, despite the estimated figure of 78.02 B MXN. In the next quarter, revenue is expected to reach 67.01 B MXN.
REGN net income for the last quarter is 19.13 B MXN, while the quarter before that showed 26.41 B MXN of net income which accounts for −27.57% change. Track more REGENERON PHARMACEUTICALS INC financial stats to get the full picture.
Yes, REGN dividends are paid quarterly. The last dividend per share was 17.89 MXN. As of today, Dividend Yield (TTM)% is 0.15%. Tracking REGENERON PHARMACEUTICALS INC dividends might help you take more informed decisions.
REGENERON PHARMACEUTICALS INC dividend yield was 0.00% in 2024, and payout ratio reached 0.00%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 24, 2025, the company has 15.11 K employees. See our rating of the largest employees — is REGENERON PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMACEUTICALS INC EBITDA is 95.85 B MXN, and current EBITDA margin is 32.79%. See more stats in REGENERON PHARMACEUTICALS INC financial statements.
Like other stocks, REGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REGENERON PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REGENERON PHARMACEUTICALS INC stock shows the sell signal. See more of REGENERON PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.